Andere talen Neurocrine Biosciences, Inc. Deutsche Boerse AG

Aandelen

NB3

US64125C1099

Beurs gesloten - Deutsche Boerse AG Andere beurzen 18:28:09 31-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
124 ^EUR	+0,61%		-4,36%	+4,38%

31/05	Neurocrine Biosciences Insider verkocht aandelen ter waarde van $5.338.565, volgens een recente SEC filing	MT
28/05	Neurocrine Biosciences zegt dat CEO Kevin Gorman met pensioen gaat	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing	31/05
Neurocrine Biosciences Says CEO Kevin Gorman Retiring	28/05
Neurocrine founder-CEO Gorman to retire in October	28/05
Neurocrine CEO set to retire	28/05
Neurocrine Biosciences Announces CEO Changes	28/05
NEUROCRINE BIOSCIENCES, INC. : UBS persiste à l'achat	28/05
Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing	21/05
Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis	21/05
Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing	16/05
Transcript : Neurocrine Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM	14/05
Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024	14/05
Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024	09/05
Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	08/05
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024	07/05
Neurocrine Biosciences Presents CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024	03/05
NEUROCRINE BIOSCIENCES, INC. : UBS persiste à l'achat	02/05
NEUROCRINE BIOSCIENCES, INC. : Oppenheimer reste à l'achat	02/05
Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell	01/05
Transcript : Neurocrine Biosciences, Inc., Q1 2024 Earnings Call, May 01, 2024	01/05
Neurocrine Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Neurocrine Biosciences, Inc. Deutsche Boerse AG

Aandelen

NB3

US64125C1099

Andere talen

Filters